Cargando…

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

BACKGROUND: To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribas, Antoni, Kirkwood, John M, Atkins, Michael B, Whiteside, Theresa L, Gooding, William, Kovar, Andreas, Gillies, Stephen D, Kashala, Oscar, Morse, Michael A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724499/ https://www.ncbi.nlm.nih.gov/pubmed/19640287 http://dx.doi.org/10.1186/1479-5876-7-68

Ejemplares similares

In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2014)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
por: Connor, Joseph P, et al.
Publicado: (2013)

Utilizing Immunocytokines for Cancer Therapy
por: Runbeck, Erin, et al.
Publicado: (2021)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

The present and future of immunocytokines for cancer treatment
por: Gout, Dennis Y., et al.
Publicado: (2022)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
por: Bishop, Michael W., et al.
Publicado: (2020)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Immunocytokines: a review of molecules in clinical development for cancer therapy
por: List, Thomas, et al.
Publicado: (2013)

Development of interferon γ-based immunocytokines targeting renal cancer
por: Chen, Peirong, et al.
Publicado: (2013)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2
por: Silver, Aliyah B., et al.
Publicado: (2023)

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses
por: Uhl, Wolfgang, et al.
Publicado: (2013)

The Premalignant Ancestor Cell of t(14;18)(+) Lymphoma
por: Brisou, Gabriel, et al.
Publicado: (2021)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
por: Jung, Keunok, et al.
Publicado: (2022)

Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020)

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
por: Waldhauer, Inja, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Correction: Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Publicado: (2020)

The Influence of Arginine on the Response of Enamel Matrix Derivative (EMD) Proteins to Thermal Stress: Towards Improving the Stability of EMD-Based Products
por: Apicella, Alessandra, et al.
Publicado: (2015)

1418. Clinical Characteristics of Vertebral Osteomyelitis in Cancer Patients
por: Fukushima, Kazuaki, et al.
Publicado: (2019)

The energy consumption structure and African EMDEs' sustainable development
por: Le, Hoang Phong, et al.
Publicado: (2020)

Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma
por: Nambiar, Mridula, et al.
Publicado: (2011)

FLUID PHASE DESTRUCTION OF C2(hu) BY C1(hu) : II. UNMASKING BY C4i(hu)OF C1(hu) SPECIFICITY FOR C2(hu)
por: Gigli, Irma, et al.
Publicado: (1969)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
por: Casadesús, Ana Victoria, et al.
Publicado: (2022)

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
por: Salaverria, Itziar, et al.
Publicado: (2023)

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.
por: Pezzella, F., et al.
Publicado: (1992)

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
por: Abbott, David R., et al.
Publicado: (2009)

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2015)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
por: Paoloni, Melissa, et al.
Publicado: (2015)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ahc1p9ng5skiignlk78j15e57